English to French Other Medical (general)

59. Please rate your AGREEMENT with the following statements on a scale of 1-5 where “1” is “Strongly Disagree” and “5” is “Strongly Agree”
a. I am comfortable that biosimilar ESAs are comparable to other reference ESA products
b. I am concerned about using an ESA product in my CKD-ND patients that is dosed beyond monthly dosing intervals (i.e. Q8W)
c. A hemoglobin less than 10g/dL presents more risk for patients than a hemoglobin of >12g/dL
d. ESA safety issues are more pronounced for oncology patients than for renal patients
e. Thrombotic side effect with high Hb are primarily due to high EPO doses
f. I have a good understanding of the differences between biosimilar ESA products and their ESA reference agents
g. EPO hypo-responders should not be treated with ESAs
h. My use of biosimilar agents would increase if there were a longer acting formulation